Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 968 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Antihypertensive Therapy Adherence

NCT04029883
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Text Message, Behavior Economic Incentive
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069
View directory record Official record
Conditions
Leukemia
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Thriving in the Midst of Moral Pain: The Acceptability and Feasibility of Acceptance and Commitment Therapy for Moral Injury (ACT-MI) Among Warzone Veterans

NCT03760731
View directory record Official record
Conditions
Moral Injury
Interventions
Acceptance and Commitment Therapy for Moral Injury (ACT-MI), Present Centered Therapy for Moral Injury (PCT-MI)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
View directory record Official record
Conditions
Heart Diseases
Interventions
Metoprolol Tartrate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Improving Symptom Trajectories of Tic Disorders and Co-occurring Diagnoses: The Role of Integrative Intensive Intervention

NCT04878302
View directory record Official record
Conditions
Tic Disorder, Childhood, Comorbidities and Coexisting Conditions
Interventions
Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

NCT03461718
View directory record Official record
Conditions
Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions
Ketamine, Midazolam injection, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

NCT04419857
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High-calorie formula
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05225675
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Scottsdate, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 20, 2026, 4:45 PM EDT
Recruiting Not applicable Interventional

IMST for Dementia Risk Reduction

NCT07349706
View directory record Official record
Conditions
Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions
Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance
Device
Lead sponsor
Florida State University
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

NCT04968990
View directory record Official record
Conditions
Wilms Tumor
Interventions
Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection, Surgical Resection, Partial Nephrectomy
Device · Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of an Opioid Sparing Pain Regimen in Cardiac Surgery

NCT03679013
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Oral Gabapentin and Intravenous Acetaminophen (IV APAP), Opiate based pain regimen.
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 20, 2026, 4:45 PM EDT
Not listed Phase 3 Interventional

Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT

NCT05011149
View directory record Official record
Conditions
Patent Ductus Arteriosus After Premature Birth
Interventions
Ibuprofen
Drug
Lead sponsor
IWK Health Centre
Other
Eligibility
Up to 72 Hours
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Orange, California • San Diego, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 20, 2026, 4:45 PM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

NCT07605897
View directory record Official record
Conditions
Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions
Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY)
Other · Drug
Lead sponsor
Joseph Spataro
Federal
Eligibility
18 Years to 69 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Recruiting Not applicable Interventional

Renal Pelvic Denervation Pilot Trial

NCT07005050
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RPD, Active hypertension medical therapy
Device · Drug
Lead sponsor
Verve Medical, Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Surprise, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

NCT04079010
View directory record Official record
Conditions
Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions
BFR, Arginine, Placebo Pill
Procedure · Dietary Supplement
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Oct 20, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 20, 2026, 4:45 PM EDT